Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Myasthenia Gravis × Tablets × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 18 Neoplasms 9 Polycystic Ovary Syndrome 8 Multiple Myeloma 4 Melanoma 4 Vomiting 3 Prostatic Neoplasms 3 Neoplasm Metastasis 3 Leukemia, Myeloid, Acute 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Skin Neoplasms 2 Sarcoma 2 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Obesity 2 Nausea 2 Lung Neoplasms 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia, B-Cell 2 Leukemia 2 Insulin Resistance 2 Inflammation 2 Diabetes Mellitus 2 Colorectal Neoplasms 2 Cognitive Dysfunction 2 Cardiotoxicity 2

Interventions

rozanolixizumab 9 zilucoplan 7 efgartigimod alfa 7 telitacicept 6 Rituximab 6 Cyclophosphamide 6 fludarabine 5 eculizumab 5 Prednisone 5 Pyridostigmine Bromide 4 Hizentra 4 ravulizumab 3 Tacrolimus 3 HBM9161 3 Amifampridine 3 thymoglobulin 2 inebilizumab 2 Prednisolone 2 Mycophenolic Acid 2 Immunoglobulins, Intravenous 2 tofacitinib 1 tocilizumab 1 satralizumab 1 sargramostim 1 rhoA GTP-Binding Protein 1 remibrutinib 1 prednylidene 1 iptacopan 1 gamma-Globulins 1 deltacortene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03914638 2020-04-06

BETA-MG

University of Aarhus

Phase 2/3 Unknown

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡